WO1995010508A1 - Derive d'oxazolinone presentant une activite inhibitrice de la phospholipase a2 intracellulaire - Google Patents
Derive d'oxazolinone presentant une activite inhibitrice de la phospholipase a2 intracellulaire Download PDFInfo
- Publication number
- WO1995010508A1 WO1995010508A1 PCT/JP1994/001716 JP9401716W WO9510508A1 WO 1995010508 A1 WO1995010508 A1 WO 1995010508A1 JP 9401716 W JP9401716 W JP 9401716W WO 9510508 A1 WO9510508 A1 WO 9510508A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituent
- phenyl
- compound
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention Okisazorinon derivative conductor having an intracellular phospholipase A 2 inhibitory activity, and to intracellular phospholipase A 2 inhibitory agent containing the Okisazorinon derivative.
- Okisazorin one having active 2-one and O key Sazorijin - 2-one derivatives and to intracellular phospholipase A 2 inhibitors containing the derivatives.
- Phospholipase A 2 is a protein that hydrolyzes the 2-acyl ester bond of phospholipids, and includes distinct intracellular PLA 2 and secreted PLA 2 . It is known that intracellular PLA 2 (cPLA 2 ) selectively hydrolyzes arachidonic acid-containing phospholipids esterified at the 2-position.
- Okisazorinon derivatives are already disclosed are various, they central muscle relaxant action or a phospholipase A 2 inhibition are described as having an effect [JP 61- 286375, US 5, 071, 988 No. 52-10874].
- the present inventors focused on attractive activity of such c PLA 2, was developed materials useful for treating inflammatory diseases by harming inhibitory its activity. Since the compounds of the present invention inhibit the action of cP LA 2, suppress free Arakidon acid from phospholipids, thereby various prostanoids prostaglandin called Arakidon acid cascade one de suppress the generation of Roikotoryen, inflammatory mediators It is expected to attenuate the effect.
- the invention is based on the formula:
- a and b each represent a carbon atom
- bond between a and b indicates that it is a single bond or a double bond
- X is hydrogen, an aryl group which may have a substituent, a heteroaryl group which may have a substituent, or an aralkyl group which may have a substituent;
- Y is hydrogen, an aryl group which may have a substituent, an aralkyl group which may have a substituent or a carboxy group or a related functional group thereof;
- Z is hydrogen, an alkyl group which may have a substituent, an alkenyl group which may have a substituent, an alkynyl group which may have a substituent, an aralkyl group which may have a substituent
- Xylalkyl group arylcarbonyl group optionally having substituents, arylsulfonylalkyl group optionally having substituents, heteroarylsulfonylalkyl group optionally having substituents, substitution A substituted or unsubstituted aminoalkyl group, a substituted or unsubstituted carboxyalkyl group or a related functional group, a substituted or unsub
- the compound represented by the above formula is a stereoisomer May be present, but the compound includes all optically active substances and mixtures thereof.
- the compounds of the present invention can be divided into several categories:
- X and Y are each independently phenyl or phenyl which may have a substituent
- Z is an aralkyl group which may have a substituent, a heteroarylalkyl group which may have a substituent, an aryloxyalkyl group which may have a substituent, and which may have a substituent
- X and Y are each independently phenyl which may have a substituent, and Z is an alkyl group which may have a substituent, an alkenyl group which may have a substituent or a substituent.
- Z is an alkynyl group which may be possessed (except when Z is a methyl group);
- X and Y are each independently phenyl which may have a substituent
- R 1 and R 2 are the same or different, and d—C 4 alkyl or a formula: ⁇ ′, 0 or — ⁇ ′, NR 4 (where R 4 is Ci—c 4 alkyl or a phenyl group which may have a substituent), or a formula:
- n 1 or 2
- Ri and R 2 are as defined above
- R3 is d-C 4 ⁇ Alkyl
- X represents a halogen atom
- X is a sulfonyl hydrazide group, a sulfonamide group, phenyl, or phenyl optionally substituted by 1 SO 3 H;
- Y is phenyl
- X and Y are the same and are phenyl substituted by a carboxy group or a related functional group
- X is phenyl
- Y is phenyl substituted by phenyl
- X is phenyl which may have a substituent or aralkyl which may have a substituent
- Y is hydrogen
- X is phenyl which may have a substituent or aralkyl which may have a substituent
- Y is hydrogen
- Z is an aralkyl which may have a substituent, a heteroarylalkyl which may have a substituent, an aryloxyalkyl which may have a substituent or an aralkyl which may have a substituent
- X is phenyl
- Y is a carboxy group or a related functional group
- Z is hydrogen or an optionally substituted aralkyl compound (unless Y is —COOCH 3 and is dihydrogen);
- the bond between a and b is a single bond
- X is hydrogen
- Y is an aralkyl group which may have a substituent
- a compound wherein Z is an alkenyl group which may have a substituent is an alkenyl group which may have a substituent.
- the "aryl group” in the “aryl group optionally having substituent (s)" in X includes phenyl, naphthyl and the like, and preferably phenyl.
- the "aralkyl group” in the “optionally substituted aralkyl group” is a C i -C 6 alkyl group which may be branched, which is substituted with an aryl group, such as benzyl, phenethyl, and benzyl. Enylpropylphenylbutyl, ( ⁇ or /?-) Naphthylmethyl and the like, preferably benzyl.
- Heteroaryl group in “heteroaryl group optionally having substituent (s)” means a 5- or 6-membered aromatic ring having one or more nitrogen, oxygen and / or sulfur in the ring and having aromaticity. However, these may be condensed with a benzene ring.
- Chenil Examples thereof include furyl, pyrrolyl, imidazolyl, virazolyl, pyridyl, pyrimidinyl, quinolyl, isoxazolyl and the like, and preferably phenyl.
- substituted aralkyl group or the “optionally substituted heteroaryl group” is exemplified by alkyl, alkoxy, halogen, phenyl and the like. The above can be replaced.
- the “carboxy group or its related functional group” in Y includes the formula:
- aryl group optionally having substituent (s)” and “aralkyl group” in Y have the same meaning as in X.
- Preferred Y is hydrogen or phenyl group.
- substituteduent in the "which may Ariru group having a substituent” sulfonyl Ruhidorajido group, sulfonamide de group, carboxy group or a related functional group, halogen, alkyl, alkoxy, Ariru, S0 3 H, S0 such as 2 C 1 or S0 2 0 (CH 2) 3 Br and the like.
- sulfonamide group examples include ammonia, pyrrolidine, piperidine, piperazine, morpholine, N-methylbiperazine, N-aralkylpiperazine, N-alkylsulfonylbiperazine, N-arylsulfonylbiperazine, piperidylalkyla Min, piperazylalkylamine, morpholylalkylamine, N-alkylpiperidylamine, N-aralkylpyridylamine, pyridinylalkylamine, carboxyphenylamine, carbamoylphenylamine, bromoalkylamine, etc. And sulfone amides containing an amino derivative.
- the preferred "sulfonamide I has the formula
- the carboxy group or its related functional group has the formula -COOH, one COOCH 3 , -CONHNH 2 ,
- a preferred group is a carboxyl group.
- Halogen refers to groups such as fluoro, chloro, bromo.
- Alkyl means straight or branched C i -C 6 alkyl, including methyl, ethyl, propyl and the like.
- Alkoxy means linear or branched d—C 6 alkoxy ′, and includes methoxy, ethoxy, propoxy, butoxy, bromobutoxy and the like.
- aryl group examples include phenyl, naphthyl and the like.
- the “alkyl group” in the “alkyl group optionally having substituent (s)” means a linear or branched C i-C 6 alkyl, and includes methyl, ethyl, n— Propyl, i-propyl, n-butyl, i-butyl, n-pentyl, i-pentyl, n-hexyl, neohexyl, and the like.
- Alkenyl group in the "which may alkenyl group having a substituent” means a straight or branched C z-C i 5 alkenyl, vinyl, Ariru, propenyl, butenyl, pentenyl, prenyl , Geranyl, furnesyl, neryl, 3,7-dimethylocten-6-yl and the like, and the “alkynyl group” means a linear or branched C 2 —C 7 alkynyl; ethynyl , 1-, 2-brovinyl, 1-, 2-, 3-butynyl.
- the “aralkyl group” in the “optionally substituted aralkyl group” has the same meaning as defined for X, and is preferably benzyl.
- aminoalkyl group which may have a substituent includes a compound represented by the formula:
- the “carboxyalkyl group which may have a substituent or its related functional group” includes _CH 2 COOH, one CH 2
- alkylsulfonyl group in the “alkylsulfonyl group optionally having substituent (s)” means C i-C 6 alkylsulfonyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, pentylsulfonyl, Hexylsulfonyl and the like.
- the “arylsulfonyl group” in the “arylsulfonyl group optionally having substituent (s)” includes phenylsulfonyl, (or) naphthylsulfonyl and the like.
- heteroarylsulfonyl group in the “heteroarylsulfonyl group optionally having substituent (s)” include, for example, chenylsulfonyl, furylsulfonyl, Examples include pyrrolylsulfonyl, imidazolylsulfonyl, virazolylsulfonyl, pyridylsulfonyl, pyrimidinylsulfonyl, quinolylsulfonyl, isoxazolylsulfonyl and the like.
- Optionally substituted alkyl group includes d—C 4 alkyl, C 3 —C 6 cycloalkyl, d—C 3 alkoxy, methoxycarbonyl, phenyl, nitrogen, carboxy, nitro and the like. Can be replaced by one or more
- Aryl alkenyl group optionally having substituent (s) "heteroaryl alkyl group optionally having substituent (s)”, “heteroaryl alkenyl group optionally having substituent (s)”, " An aryloxyalkyl group optionally having a substituent, an “aralkyloxyalkyl group optionally having a substituent”, an aryloxycarbonyl group optionally having a substituent ,
- the "arylsulfonylalkyl group optionally having substituent (s)” and the “heteroarylsulfonylalkyl group optionally having substituent (s)” have the same meanings as defined in X.
- alkenyl moiety and the alkyl moiety have the same meaning as defined in Z.
- substituted by one or more is exemplified by alkyl, alkoxy, halogen, phenyl, trifluoromethyl and the like, and these may be substituted by one or more.
- the compound according to the present invention can be synthesized according to a conventional method. Next, a general synthesis method of the compound will be described. I. Oxazolinone inducer
- the compound of the present invention can be synthesized mainly according to the method described in the literature (GH Hakimelahi, CB Boyce, and HS Kasmai, Helvetica Chim. Acta 342 (1977)).
- the target compound is obtained by heating the benzoin compound 1 and the carbamic acid ester in the presence of an acid or a base.
- X and Y may be an aryl group or an aralkyl group other than a benzene ring, and the ester residue of carbamic acid may be a commonly used alkyl, aryl or aralkyl such as methyl, ethyl, propyl, phenyl, or benzyl.
- the acid used as the catalyst may be a commonly used acid such as hydrochloric acid, sulfuric acid, polyphosphoric acid, toluenesulfonic acid, phosphoric acid and the like.
- Base catalysts include pyridine, triethylamine, 4,4-dimethylaminopyridine, N, N-diisopropylethylamine, 1,5-diazabicyclo [4.3.0] non-1-ene (DBN), 1 , 4-Diazabicyclo [2.2.2] octane (DABC ⁇ ), 1,8-Diazabicyclo [5.4.0] indene 7-ene (DBU), potassium carbonate, sodium carbonate, potassium hydroxide, sodium hydroxide Pum etc. are used.
- the reaction is usually achieved by heating at 60-200, preferably at 100-180, for 1 hour to 48 hours, preferably 8 hours to 30 hours.
- a solvent ⁇ , ⁇ -dimethylformamide (DMF), dimethylsulfoxide (DMSO) or the like may be used, but the desired product can be obtained in good yield without a solvent.
- chlorosulfonic acid is allowed to act on the 4,5-diaryloxazoline-12-one £ _ obtained by the above 1) -i) method.
- various amines are allowed to act on the derivative to form a sulfonamide.
- chlorosulfonation occurs at the aromatic ring X and does not occur at Y, as revealed by measurement of NOE by iH NMR using a chlorosulfonyl derivative.
- Chlorosulfonated in a solvent such as CHC1 3, CH 2 C1 2, 0-1 00 preferably accomplished by reacting 1 hour to 6 hours at 20 ° to 60.
- Ammonia, pyrrolidine, piperidine, piperazine, morpholine, N-methylbiperazine, piperidylalkylamine, morpholylalkylamine, N-alkylpiperidine, including ammonia are derived as sulfamine compounds.
- Amine N-aralkylpiperidylamine, pyridinylalkylamine, carboxyphenylamine, rubamoylphenylamine, hydrazine, 1-aminopyrrolidine, 1-aminobiperidine, 4-amino-1,2
- 4-triazole 1-amino-1-methylbiperazine, 4-aminomorpholine, 1,4-diaminobiperazine, and the like, there are also commonly used amino derivatives and hydrazine derivatives.
- oxazolin-2-one derivatives which are X ⁇ Y (X and Y are each an aryl group or an aralkyl group) can be obtained by a method described in the literature (B. Zwanenburg et al., J. Org. Chem., ⁇ 2231 (1984)).
- R alkyl
- Oxazolin-1-ones having a carboxylic acid or its related functional group at the 4-position are synthesized according to the method of C-g. Shin et al. (Chem. Lett., 1171 (1982)).
- —Acetyl chloride-dithionyl chloride is allowed to act on dehydroamino acid to form cyclic anhydride T_.
- an alcoholic solvent such as methanol
- a halogenating agent such as mosmosimidin (NBS) or N-chlorosuccinimid (NCI)
- NSS mosmosimidin
- NCI N-chlorosuccinimid
- pyridine triethylamine
- DMAP ⁇ -dimethylaminopyridine
- Y is a carboxylic acid ester group such as a methyl ester. This is hydrolyzed and converted into various carboxylic acid derivatives such as amides to produce another compound of the present invention.
- the synthesis of the compound of the present invention can be achieved by using various 2-amino alcohol derivatives as raw materials and closing the ring to oxazolidin-2-ones by an appropriate reagent or reaction.
- optically active 2-amino alcohols two kinds (when X or Y is hydrogen) or four kinds of optically active substances oxazolidin-one-two-class s ' stereoselective Obviously, it can be synthesized as follows.
- These optically active 2-amino alcohols are synthesized by the method of SDBurke et al. (Tetr. Lett., 28, No. 34, 3105, 1987), which synthesizes mono-protected vicinal glycols from optically active a-alkoxy esters. Ability to apply and synthesize amino acid esters? it can.
- R 1 Amino protecting group
- R 2 alkyl or lower alkyl
- the ester intermediate is first obtained by reduction of the ester, which is subjected to the next Grignard reaction at one point without isolation.
- the intermediate aldehyde forms a chelation with the metal derived from the reducing agent, and the structural specificity of the chelation controls the stereochemistry of the next Grignard reaction. Therefore, the stereochemistry of the product, 2-aminoethanols, can be controlled by the type of metal hydride, which is the reducing agent.
- Such reducing agents include lithium borohydride, lithium tri-tert-butoxy.aluminum hydride, diisobutylaluminum hydride, and other metal hydrides normally used for the reduction of esters to aldehydes. Is mentioned.
- a reagent capable of introducing a substituent X at the 5-position of oxazolin-1-ones in a later step
- examples thereof include phenylmagnesium bromide
- the reaction solvent ether solvents such as ether, tetrahydrofuran, and dimethoxetane are used, and the reaction is usually carried out at 100 ° to 40 °, preferably at 180 ° to 0 °.
- Such 2-amino alcohols include commercially available products, and can be used as raw materials for synthesizing the oxazolidin-1-ones according to the present invention.
- a ring-closing reaction from 2-amino alcohols to oxazolidin-12-ones is performed.
- phosgene or its stable derivative, triphosgene is used in a solvent such as ether, tetrahydrofuran, methylene chloride, benzene, or toluene at 0 ° to 30 ° in the presence of a commonly used base such as triethylamine or pyridine. And subjected to a ring closure reaction.
- R alkyl, aralkyl
- a metal hydroxide such as NaOH or KOH, or a commonly used organic base such as triethylamine or DBU is used, and is used in tetrahydrofuran, water, methanol, or a mixed solvent thereof at 0 ° to 30 ° C. Let react.
- AQ that is, oxazolin-1-one derivative ⁇ ⁇ Halogen in the presence of strong bases such as sodium hydride, n-butyl lithium, potassium hydride, potassium t-butoxide, lithium 'diisopropylamide, sodium' amide
- Alkyl halides alkenyl halides, alkynyl halides, aralkyl halides
- halides such as alkyl, alkyloxycarbonyl halide, arylalkyloxycarbonyl halide, arylarylcarbonyl halide, alkylsulfonyl halide, arylsulfonyl halide, etc. are reacted to obtain the desired product.
- the solvent examples include tetrahydrofuran, getyl ether, dioxane, benzene, toluene, dimethylformamide (DMF), dimethylacetamide (DMA), dimethoxetane, and dimethylsulfoxide (DMS0).
- the present reaction is carried out at a temperature of from 180 to 100, preferably from 120 to 60.
- N-substituted oxazolin-1-ones may be synthesized by introducing an amino compound using cyclic carbonate ⁇ _ as a raw material in addition to the N-substitution reaction described in (1) above. (J. Sheehan et al., J. Org. Chera., 38, Nol7, 3034 (1973))
- Oxazolin-12-ones are obtained by reacting various amines with the cyclic carbonate synthesized from the R S benzoine derivative and phosgene, and subsequently reacting with trifluoroacetic acid (TFA).
- TFA trifluoroacetic acid
- the reaction between carbonate and amine is usually carried out in DMF at around room temperature.
- the resulting unstable intermediate is converted to oxazolin-12-one ⁇ _ in TFA, also at room temperature. According to this method, compounds which are difficult to react with oxazolin-12-ones and halides as described in II) -1) can be easily synthesized.
- the quaternary salts have the power to make amines act on the raw material halides, It is synthesized by a conventional method, such as by the action of alkylogenide. Solvents such as methanol, ethanol, tetrahydrofuran, methylene chloride, and getyl ether are used, and the reaction is usually carried out at room temperature to about 100.
- the present invention provides a compound represented by the formula:
- a and b each represent a carbon atom
- bond between a and b indicates that it is a single bond or a double bond
- X is hydrogen, an aryl group which may have a substituent, a heteroaryl group which may have a substituent, or an aralkyl group which may have a substituent;
- Y is hydrogen, an aryl group which may have a substituent, an aralkyl group which may have a substituent, or a carboxy group or a related functional group;
- Z is hydrogen, an alkyl group which may have a substituent, an alkenyl group which may have a substituent, an alkynyl group which may have a substituent, an aralkyl group which may have a substituent
- the pharmaceutical composition of the present invention has the formula:
- compositions containing the known compounds of formula (I) are also encompassed. According to the experiments conducted by Hoshikisha et al., These known compounds were also found to be cytosols PLA.
- the known compounds 001 and 002 are easily produced according to the method of Reference Example 1. can do.
- the pharmaceutical composition of the present invention can be applied to both oral and parenteral routes, it can be formulated into oral preparations, injections, ointments and the like.
- the dose of the compound according to the present invention varies depending on the intended therapeutic effect, administration route, patient age, body weight, severity of the disease, etc., but usually the daily dose is 50 mg to 100 O mg. Usually, the daily dose is divided into 2 to 5 divided doses.
- the pharmaceutical compositions of the present invention can be formulated in unit dosage forms containing the divided doses.
- ⁇ Nujol '' is Nudiol
- ⁇ neat '' is thin film
- ⁇ base peak '' is reference zeek
- ⁇ MeOH '' is methanol
- ⁇ EtOH '' is ethanol
- ⁇ EtOAc '' or ⁇ AcOEt '' is ethyl acetate.
- DMSO means dimethyl sulfoxide
- DMF means N, N-dimethylformamide
- THF means tetrahydrofuran
- eq means equivalent
- Ph means phenyl group. I do.
- Example 2 The same reaction as in Example 1 was carried out to obtain a compound group described in the following table.
- Example 1 (1) 200 mg, 0.84 ol.
- Example 1 (1) 200 mg, 0.84 ol.
- 950 mg (4.2 liters) of 2-naphthalenesulfonyl chloride was dissolved in 3 ml of benzene, added at room temperature, and stirred for 1.5 hours.
- Ethyl acetate and water were added and the mixture was partitioned, and the organic layer was dried. The solid was recrystallized from ethyl acetate and dichloromethane to give 152 mg of the compound.
- Example 27 The same reaction as in Example 27 was performed to obtain a compound group shown in the following table.
- IR liquid film: 685, 702, 723, 745, 751, 965, 1025, 1 066, 1070, 1146, 1161, 1193, 1355, 1368, 1381, 1395, 1451, 1498, 1601, 1 753, 2940, 2985, 3
- Example 1 After dissolving the lii conjugate (500 mg, 2.lmmol) and 723 mg (2.4 mmol) of benzhydryl bromoacetate prepared in (1) in 3 ml of DMF, the mixture was dissolved in a stream of N 2. Under ice-cooling, add 100 mg of NaH (60% inoil) in small portions. After the addition, return to room temperature and stir for 2 hours. The reaction solution is poured into cold water and extracted with AcOEt. The organic layer is washed with water and saturated saline, dried over Na 2 SO 4 , and concentrated under reduced pressure to obtain 994 mg of a pale brown candy.
- Example 40 Compound wherein R is n-butyl
- R is the formula:
- Example 51 1 3- (3-fluorobenzyl) -1,4,5-diphenyloxa Zone 2-On (0039)
- Example 59 Compound 0057 Melting point: 123-124 (EtOAc)
- Example 62 (0054)
- Example 60 4,5-bis- (4-methoxycarbonylphenyl) -1-3-oxoxolin-1-one (0020)
- N-laurylthiazol bromide (2.01 g, 6 olol) synthesized according to the literature [W. Tagaki, Bull Chemical Society Japan (1980)] was added to 1 liter of phosphate buffer (0.5moK pH 8). ), Add methyl 4-formylbenzoate (9.85 g, 6 Ommol) with stirring at room temperature, heat at 55 for 6 hours, leave at room temperature for 2 days, filter the precipitated crystals, and dissolve in ethyl acetate The extract was washed with water, dried over sodium sulfate, filtered, and concentrated. The obtained residue was recrystallized from ethyl acetate to obtain 7.23 g (73%) of a product.
- Example 6 3 Benzyl-4,5-bis- (4-methoxycarbonylphenyl) -1-oxazolin-12-one (0046)
- Example 62 3-benzyl-4,5-bis (4-hydroxycarbonylphene Nil) one-three-year-old xazoline one two-one (0054)
- Example 60 Using the compound 0020 produced in Example 60 as a starting material, the reaction was carried out in the same manner as in Example 61 to obtain compounds 0013 and 0112.
- Example 62 Using the compound 0054 obtained in Example 62, the above compounds 0101 and 0102 were obtained.
- Example 70 (0052) Real example 68: 4,5-bis- (4-hydroxycarbonylphenyl) -13-oxazoline-1 2-one (0022)
- Example 60 Using compound 0020 produced in Example 60 as a starting material, the reaction was carried out in the same manner as in Example 62 to obtain compound 0022.
- Example 68 The oxazolic acid obtained in Example 68 (12, 163 mg, 0.5 tmol) was suspended in 2 ml of dry dichloromethane, and stirred with DMF (13 Oxalyl chloride (1/10 volume) and mix with oxalyl chloride (131 The mixture was left at room temperature for 76 hours, and dichloromethane was added. The precipitated precipitate was collected by filtration, washed and dried to obtain 149 mg (82%) of the title compound 0053.
- DMF 13 Oxalyl chloride (1/10 volume
- oxalyl chloride 131
- dichloromethane was added.
- the precipitated precipitate was collected by filtration, washed and dried to obtain 149 mg (82%) of the title compound 0053.
- Example 73 (0028)
- Example 7 2 5- (3-bromopropylaminosulfonylphenyl) -14-phenyl-14-oxazoline-12-one (003)
- the title compound 0073 was obtained by benzylating a compound described in the literature (J. Org. Chem., 49, 2231 (1984)), 5-phenyl-14-year-old xazolin-12-one.
- KS 9 compound 7.1 lg (21.5 tmol) was suspended in 100 ml of methylene chloride, and at 0, oxalyl chloride 6.57 ml (21.5 mmol X 3.5), dimethylform Add 2 drops of amide and stir at room temperature for 40 minutes. The reaction mixture is concentrated, THF is added to the residue, and the mixture is concentrated again to obtain pale yellow crystals. To this is added 100 ml of THF and 14.28 ml of trimethylsilyl azide (21.5 mol x 5.0) at room temperature, and the mixture is distilled at 85 for 5 hours and 15 minutes. The reaction solution was cooled and concentrated.
- reaction solution is poured into water, extracted with methyl ethyl ketone, washed with saturated saline, dried over magnesium sulfate, and concentrated under reduced pressure.
- the residue was purified by Si0 2 Karamukuro
- the fraction eluted with methylene chloride-methyl alcohol (10: 1) was collected by chromatography to obtain 228 mg of a foamy residue. After washing with ethyl ether, 193 mg of the desired product is obtained in an amorphous form (61.0%).
- Example 82 The compound prepared in Example 82 was converted into a quaternary salt with CH 3 I by a conventional method. C Yield: 61%
- Image R 5 CD 30 D (ppm): 1.60 to 2.00 (m, 6H), 3.17 (s, 3H), 3.37 to 3.83 (m, 8H), 7.40 to 7.50 (m, 3H), 7.74 ⁇ 7.87 (m, 2 H)
- I R (cm-i, KBr): 695, 745, 760, 1365, 1445, 1495, 1600, 1 755, 2950, 3020, 3400
- I R (cm-i, neat): 700, 755, 765, 1025, 1055, 1360, 1390, 1450, 1500, 1605, 1760, 2950
- reaction is carried out in the same manner as in Reference Example 2 except that D-(-)-phenylglycine methyl ester hydrochloride is used as a starting material.
- Example 10 7 Compound 0 3 4 6
- the solvent of the washing solution is distilled off under reduced pressure.
- the residue is made acidic by adding aqHCl, and extracted with ethyl acetate. After drying the ethyl acetate layer, the solvent was distilled off to obtain 686 mg (19%) of free carboxylic acid as colorless crystals.
- Example 1 17 5-bis-4-biphenyl) _- 3-benzyl-1-4-phenyloxazolin-1-one (1-35) (0089)
- Oxalyl chloride (13.6 ml, 152 mmol) was added dropwise to a solution of Na salt (1-40) (2.58 g, 7.62 mmol) in THF (38 ml) under ice cooling, and the mixture was stirred at the same temperature for 30 minutes. After further stirring at room temperature for 1.5 hours, the solvent is distilled off under reduced pressure. The obtained residue is dissolved in THF (38 ml), Me 3 SiN 3 (5.32 ml 38.lmmol) is added, and the mixture is refluxed for 4 hours. Reaction solvent was distilled off, the residue CHC1 3 - MeOH washing was dissolved in (9/1), distilled off after drying the solvent. The resulting cream colored crystalline residue THF-Et 2 0 and recrystallized to give colorless needle crystals 1.362 g.
- Example 1 19 4- (4-biphenyl) -13-benzine-5-phenyloxazolin-1-2-one (I-43) (0 145)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94929652A EP0675114A1 (en) | 1993-10-15 | 1994-10-13 | Oxazolinone derivative having intracellular phospholipase a 2? inhibitor activity |
AU78632/94A AU684316B2 (en) | 1993-10-15 | 1994-10-13 | Oxazolinone derivative having intracellular phospholipase A2 inhibitor activity |
KR1019950702434A KR950704278A (ko) | 1992-10-15 | 1994-10-13 | 세포내 포스포리파제 a₂저해 활성을 갖는 옥사졸리논 유도체(oxazolinone derivative having intracellular phospholipase a₂inhibitor activity) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25830993 | 1993-10-15 | ||
JP5/258309 | 1993-10-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995010508A1 true WO1995010508A1 (fr) | 1995-04-20 |
Family
ID=17318464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1994/001716 WO1995010508A1 (fr) | 1992-10-15 | 1994-10-13 | Derive d'oxazolinone presentant une activite inhibitrice de la phospholipase a2 intracellulaire |
Country Status (7)
Country | Link |
---|---|
US (1) | US5817826A (ja) |
EP (1) | EP0675114A1 (ja) |
KR (1) | KR950704278A (ja) |
CN (1) | CN1115576A (ja) |
AU (1) | AU684316B2 (ja) |
CA (1) | CA2151157A1 (ja) |
WO (1) | WO1995010508A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997005135A1 (fr) * | 1995-07-31 | 1997-02-13 | Shionogi & Co., Ltd. | Derives de pyrrolidine possedant une activite d'inhibition de la phospholipase a¿2? |
WO1998033797A1 (fr) * | 1997-01-31 | 1998-08-06 | Shionogi & Co., Ltd. | Derives de pyrrolidine ayant une activite inhibant la phospholipase a2 |
US6159990A (en) * | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
US6613790B2 (en) | 2001-04-17 | 2003-09-02 | Pharmacia Corporation | Prodrugs of COX-2 inhibitors |
JP2012077045A (ja) * | 2010-10-05 | 2012-04-19 | Toray Fine Chemicals Co Ltd | 高純度ジアシル誘導体 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2793791B1 (fr) * | 1999-05-19 | 2002-01-25 | Univ Paris 7 Denis Diderot | Nouveaux composes inhibiteurs specifiques de phospholipases a2 |
WO2003101177A2 (en) * | 2002-06-04 | 2003-12-11 | Sequenom, Inc. | Diagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions |
AU2003248794B2 (en) * | 2002-06-27 | 2007-10-04 | Harkness Pharmaceuticals, Inc. | Therapeutic methods for reducing fat deposition and treating associated conditions |
AU2003248793A1 (en) * | 2002-06-27 | 2004-01-19 | Sequenom, Inc | Diagnosing predisposition to fat deposition and associated condition |
DOP2005000123A (es) | 2004-07-02 | 2011-07-15 | Merck Sharp & Dohme | Inhibidores de cetp |
WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
WO2019190823A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
EP3864008A1 (en) | 2018-10-10 | 2021-08-18 | vTv Therapeutics LLC | Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5175521A (ja) * | 1974-12-26 | 1976-06-30 | Fuji Photo Film Co Ltd | Shashinyokaraakapuraa |
JPS5210874B2 (ja) * | 1973-07-09 | 1977-03-26 | ||
JPS5297966A (en) * | 1976-02-13 | 1977-08-17 | Kao Corp | Novel oxazolinone derivatives |
JPS53146635A (en) * | 1977-05-27 | 1978-12-20 | Kopia Kk | Cut sheets carrying device |
JPS61286375A (ja) * | 1985-06-13 | 1986-12-16 | Nippon Chemiphar Co Ltd | 新規な1,3−オキサゾリジン−2−オン誘導体およびその製造法 |
JPH03500298A (ja) * | 1988-07-12 | 1991-01-24 | セラピューティック・パッチ・リサーチ・ナムローゼ・フェンノートシャップ | オキサゾリジノン浸透促進化合物 |
JPH05239078A (ja) * | 1992-02-28 | 1993-09-17 | Santen Pharmaceut Co Ltd | 新規オキサゾリジノン誘導体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3033829A (en) * | 1958-02-06 | 1962-05-08 | Dow Chemical Co | N-vinyl-5-phenyl-2-oxazolidinone compounds and polymers |
US2975187A (en) * | 1959-03-17 | 1961-03-14 | Union Carbide Corp | Cyanoethylated oxalactams |
US3152141A (en) * | 1963-11-29 | 1964-10-06 | Dow Chemical Co | 3-(2-propynyl)-2-oxazolidinone compounds |
JPS5210874A (en) * | 1975-06-30 | 1977-01-27 | Dainippon Toryo Co Ltd | Blue luminous fluorescent display tube excited by electron beam of low velocity |
PT95690A (pt) * | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados substituidos de acidos benzoilbenzo-, bifenil- e 2-oxazol-alcanoicos, uteis como inibidores de pla2 e da lipoxigenase |
-
1994
- 1994-10-13 AU AU78632/94A patent/AU684316B2/en not_active Ceased
- 1994-10-13 KR KR1019950702434A patent/KR950704278A/ko active IP Right Grant
- 1994-10-13 CA CA002151157A patent/CA2151157A1/en not_active Abandoned
- 1994-10-13 WO PCT/JP1994/001716 patent/WO1995010508A1/ja not_active Application Discontinuation
- 1994-10-13 EP EP94929652A patent/EP0675114A1/en not_active Withdrawn
- 1994-10-13 CN CN94190792A patent/CN1115576A/zh active Pending
-
1997
- 1997-08-05 US US08/905,943 patent/US5817826A/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5210874B2 (ja) * | 1973-07-09 | 1977-03-26 | ||
JPS5175521A (ja) * | 1974-12-26 | 1976-06-30 | Fuji Photo Film Co Ltd | Shashinyokaraakapuraa |
JPS5297966A (en) * | 1976-02-13 | 1977-08-17 | Kao Corp | Novel oxazolinone derivatives |
JPS53146635A (en) * | 1977-05-27 | 1978-12-20 | Kopia Kk | Cut sheets carrying device |
JPS61286375A (ja) * | 1985-06-13 | 1986-12-16 | Nippon Chemiphar Co Ltd | 新規な1,3−オキサゾリジン−2−オン誘導体およびその製造法 |
JPH03500298A (ja) * | 1988-07-12 | 1991-01-24 | セラピューティック・パッチ・リサーチ・ナムローゼ・フェンノートシャップ | オキサゾリジノン浸透促進化合物 |
JPH05239078A (ja) * | 1992-02-28 | 1993-09-17 | Santen Pharmaceut Co Ltd | 新規オキサゾリジノン誘導体 |
Non-Patent Citations (10)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 103, Abstract No. 22883 (1985). * |
CHEMICAL ABSTRACTS, Vol. 63, Abstract No. 11542h (1965). * |
CHEMICAL ABSTRACTS, Vol. 86, Abstract No. 189783 (1977). * |
CHEMICAL ABSTRACTS, Vol. 86, Abstract No. 29695 (1977). * |
CHEMICAL ABSTRACTS, Vol. 91, Abstract No. 176651 (1979). * |
Heterocycles, Vol. 23, No. 2, (1985), SHIBUYA, SHIROSHI, "An Enantioselective Synthesis of 1-(. Alpha.-Hydroxyalkyl)1,2,3,4-Tetrahydroisoqu inolines through Optically Active N-Oxaacyliminium Ion Intermetiates", pages 395 to 398. * |
Journal of Heterocycl. Chem., Vol. 17, No. 8, (1980), GUZIEC, FRANK S. et al., "Photochemical Transformations of 4,5-Diaryl-4-Oxazolin-2-One Protecting Groups", pages 1807 to 1808. * |
Journal of Organic Chemistry, Vol. 49, No. 3, (1984), PADWA, ALBERT et al., "Stuidies Dealing with the Aza Claisen Rearrangement of 2-Allyloxy-Substituted Oxazoles", pages 399 to 406. * |
Journal of Organic Chemistry, Vol. 58, No. 12, (1993), BUSACCA, CARL A. et al., "Phenethylamines via Lleck Arylation of a New Vinylamine Equivalent", pages 3299-3303. * |
See also references of EP0675114A4 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997005135A1 (fr) * | 1995-07-31 | 1997-02-13 | Shionogi & Co., Ltd. | Derives de pyrrolidine possedant une activite d'inhibition de la phospholipase a¿2? |
AU707537B2 (en) * | 1995-07-31 | 1999-07-15 | Anthera Pharmaceuticals, Inc. | Pyrrolidine derivatives having phospholipase a2 inhibitory activity |
US5955616A (en) * | 1995-07-31 | 1999-09-21 | Shionogi & Co., Ltd. | Pyrrolidine derivatives having phospholipase A2 inhibitory activity |
CN1064682C (zh) * | 1995-07-31 | 2001-04-18 | 盐野义制药株式会社 | 具有磷脂酶a2抑制活性的吡咯烷衍生物 |
WO1998033797A1 (fr) * | 1997-01-31 | 1998-08-06 | Shionogi & Co., Ltd. | Derives de pyrrolidine ayant une activite inhibant la phospholipase a2 |
US6159990A (en) * | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
US6620815B1 (en) | 1997-06-18 | 2003-09-16 | Synaptic Pharmaceutical Corporation | Oxazolidinones and uses thereof |
US6613790B2 (en) | 2001-04-17 | 2003-09-02 | Pharmacia Corporation | Prodrugs of COX-2 inhibitors |
JP2012077045A (ja) * | 2010-10-05 | 2012-04-19 | Toray Fine Chemicals Co Ltd | 高純度ジアシル誘導体 |
Also Published As
Publication number | Publication date |
---|---|
EP0675114A4 (ja) | 1995-11-02 |
KR950704278A (ko) | 1995-11-17 |
CA2151157A1 (en) | 1995-04-20 |
US5817826A (en) | 1998-10-06 |
AU7863294A (en) | 1995-05-04 |
CN1115576A (zh) | 1996-01-24 |
EP0675114A1 (en) | 1995-10-04 |
AU684316B2 (en) | 1997-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9643927B1 (en) | Process for the preparation of kinase inhibitors and intermediates thereof | |
CA2270086C (fr) | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1248771B1 (fr) | Procede de preparation de derives de l'acide 3-hydroxypicolinique | |
WO1995010508A1 (fr) | Derive d'oxazolinone presentant une activite inhibitrice de la phospholipase a2 intracellulaire | |
US10550087B2 (en) | Process for the preparation of kinase inhibitors and intermediates thereof | |
KR20050044407A (ko) | N,n'-치환-1,3-디아미노-2-히드록시프로판 유도체 | |
AU2002359376A1 (en) | N, N'-substituted-1,3-diamino-2-hydroxypropane derivatives | |
AU3675900A (en) | Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same | |
WO2000059880A1 (en) | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | |
NO165192B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive glyserolderivater. | |
US8809584B2 (en) | N-substituted-N-phenylethylsulfonamides for the identification of biological and pharmacological activity | |
CA2369446A1 (en) | Substituted azetidin-2-ones as cysteine protease inhibitors | |
Harvill et al. | Haloalkyltetrazole and aminoalkyltetrazole derivatives | |
NO885117L (no) | Substituerte hydroksylaminer. | |
JPH0776213B2 (ja) | N,n′―ビス(アルコキシアルキル)―ピリジン―2,4―ジカルボン酸ジアミド類 | |
US20120122710A1 (en) | Libraries of n-substituted-n-phenylethylsulfonamides for the identification of biological and pharmacological activity | |
JP3207018B2 (ja) | ベンジルコハク酸誘導体の製造方法およびその製造中間体 | |
JPH06340622A (ja) | ベンジルコハク酸誘導体の製造方法およびその製造中間体 | |
RU2167863C2 (ru) | Производные бутадиена и способ их получения, производные амидобутадиена и способ их получения, производные пирролидина и способ их получения | |
JPH07291966A (ja) | (5z)−6−〔(2s,4r)−4−(4−クロロフェニルスルホニルアミノ)−1−(3−ピリジルメチル)−2−ピロリジニル〕−5−ヘキセン酸の製造方法およびその製造中間体 | |
JPH05294930A (ja) | スチリル化合物 | |
FR2758326A1 (fr) | Derives de pyridone, leur prepaparation et leur utilisation comme intermediaires de synthese | |
JP4616770B2 (ja) | 選択的なアミノ置換基導入法 | |
JPH07291965A (ja) | 新規なピロリジン誘導体 | |
JPH0812670A (ja) | 新規なピロリジン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 94190792.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2151157 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994929652 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1995 454382 Country of ref document: US Date of ref document: 19950615 Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1994929652 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1997 905943 Country of ref document: US Date of ref document: 19970805 Kind code of ref document: A |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994929652 Country of ref document: EP |